Rhofade Approval History
- FDA approved: Yes (First approved January 18th, 2017)
- Brand name: Rhofade
- Generic name: oxymetazoline hydrochloride
- Dosage form: Cream
- Company: Allergan, Inc.
- Treatment for: Rosacea
Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults.
FDA approval of Rhofade was based on the results of two randomized, vehicle-controlled clinical trials of 885 adult patients with moderate or severe rosacea. Rhofade was proven more effective than vehicle in reducing facial erythema associated with rosacea through 12 hours.
Rhofade is a topical cream applied once daily in a thin layer to the entire face, avoiding the eyes and lips. The most common side effects include dermatitis, worsening of rosacea, and itching, swelling and pain at the application site.
Development History and FDA Approval Process for Rhofade
|Jan 19, 2017||Allergan Announces FDA Approval of Rhofade (oxymetazoline hydrochloride) Cream for Facial Erythema Associated with Rosacea|
|May 24, 2016||Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.